In patients carrying AML mutated for DNMT3A and FLT3 (2022 OHSU repository in cBioPortal), low expression of FHIT correlates with reduced overall survival, suggesting that these patients could potentially benefit from DCPS targeted therapy (Fig. 1G). The gene discussed is FHIT; the disease is acute myeloid leukemia.